Skip to main content

Table 3 Summary of Riede et al.’s results on the effect of larch arabinogalactan on common cold

From: Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials

Population analysed

FASa

PPa set

Groups

Placebo

AGa

Placebo

AGa

Number of common cold episodes

1.06 ± 0.85

0.83 ± 0.82

1.10 ± 0.85

0.85 ± 0.82 *

Number of subjects affected by a cold episode

72.4 %

58.4 % *

74.4 %

59.8 % *

Duration of common cold episodes

8.3 ± 2.9

8.5 ± 2.8

-

-

Intensity of symptoms after 5 days, documented in CRFa

8.5 ± 6.6

8.4 ± 6.8

-

-

Intensity of symptoms after 5 days, from subject diary

5.85 ± 8.35

4.73 ± 8.08

-

-

Intensity of symptoms at start, documented in CRFa

11.6 ± 6.3

13.3 ± 6.6

-

-

Intensity of symptoms at start, from subject diary

11.5 ± 6.5

13.7 ± 6.9 *

-

-

  1. a AG Arabinogalactan, CRF Case Report Form, FAS Full analysis set, PP Per protocol
  2. Mean values (± SD) significantly different from the placebo: * p < 0.05